GALERA THERAPEUTICS INC (GRTX) Stock Fundamental Analysis

NASDAQ:GRTX • US36338D1081

0.145 USD
-0.07 (-32.59%)
At close: Jun 3, 2024
0.1379 USD
-0.01 (-4.9%)
After Hours: 6/3/2024, 8:18:13 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

Taking everything into account, GRTX scores 1 out of 10 in our fundamental rating. GRTX was compared to 521 industry peers in the Biotechnology industry. GRTX has a bad profitability rating. Also its financial health evaluation is rather negative. GRTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year GRTX has reported negative net income.
  • In the past year GRTX has reported a negative cash flow from operations.
  • GRTX had negative earnings in each of the past 5 years.
  • GRTX had a negative operating cash flow in each of the past 5 years.
GRTX Yearly Net Income VS EBIT VS OCF VS FCFGRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

  • The Return On Assets of GRTX (-232.80%) is worse than 91.51% of its industry peers.
Industry RankSector Rank
ROA -232.8%
ROE N/A
ROIC N/A
ROA(3y)-154.7%
ROA(5y)-120.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GRTX Yearly ROA, ROE, ROICGRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800 -1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for GRTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRTX Yearly Profit, Operating, Gross MarginsGRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, GRTX has more shares outstanding
  • GRTX has a worse debt/assets ratio than last year.
GRTX Yearly Shares OutstandingGRTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
GRTX Yearly Total Debt VS Total AssetsGRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -36.96, we must say that GRTX is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of GRTX (-36.96) is worse than 93.24% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -36.96
ROIC/WACCN/A
WACCN/A
GRTX Yearly LT Debt VS Equity VS FCFGRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M 150M

2.3 Liquidity

  • A Current Ratio of 7.54 indicates that GRTX has no problem at all paying its short term obligations.
  • The Current ratio of GRTX (7.54) is better than 67.76% of its industry peers.
  • A Quick Ratio of 7.54 indicates that GRTX has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 7.54, GRTX is doing good in the industry, outperforming 67.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.54
Quick Ratio 7.54
GRTX Yearly Current Assets VS Current LiabilitesGRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 55.27% over the past year.
EPS 1Y (TTM)55.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • GRTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.30% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y31.72%
EPS Next 2Y25.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GRTX Yearly Revenue VS EstimatesGRTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 20M 40M 60M 80M 100M
GRTX Yearly EPS VS EstimatesGRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • GRTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GRTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRTX Price Earnings VS Forward Price EarningsGRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRTX Per share dataGRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5 -2 -2.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as GRTX's earnings are expected to grow with 25.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.3%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for GRTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

GALERA THERAPEUTICS INC

NASDAQ:GRTX (6/3/2024, 8:18:13 PM)

After market: 0.1379 -0.01 (-4.9%)

0.145

-0.07 (-32.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14
Earnings (Next)08-12
Inst Owners0.66%
Inst Owner Change0%
Ins Owners49.52%
Ins Owner Change-0.2%
Market Cap7.89M
Revenue(TTM)N/A
Net Income(TTM)-45.75M
Analysts45.71
Price Target0.38 (162.07%)
Short Float %0.02%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.99
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)-0.7
OCFYN/A
SpS0
BVpS-2.48
TBVpS-2.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -232.8%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-154.7%
ROA(5y)-120.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.54
Quick Ratio 7.54
Altman-Z -36.96
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)28.65%
Cap/Depr(5y)88.72%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.89%
EPS Next Y31.72%
EPS Next 2Y25.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year110.98%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.72%
OCF growth 3YN/A
OCF growth 5YN/A

GALERA THERAPEUTICS INC / GRTX FAQ

What is the ChartMill fundamental rating of GALERA THERAPEUTICS INC (GRTX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to GRTX.


What is the valuation status for GRTX stock?

ChartMill assigns a valuation rating of 1 / 10 to GALERA THERAPEUTICS INC (GRTX). This can be considered as Overvalued.


What is the profitability of GRTX stock?

GALERA THERAPEUTICS INC (GRTX) has a profitability rating of 0 / 10.